JJDC — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Mestag Therapeutics is an immunology company developing first-in-class agonist antibody therapies for cancer and inflammatory diseases based on fibroblast biology, and operates a RAFT platform for discovering new drug targets.
AI & Machine LearningBiotechHealthtech
Susan Hill(Chief Executive Officer)inMichael B. Brenner(Founder)Chris Buckley(Founder)Mark Coles(Founder)inSoumya Raychaudhuri(Founder)David A. Tuveson(Founder)
Co-investorsGV (Google Ventures)ForbionJohnson & Johnson Innovation – JJDCNorthpond VenturesSV Health Investors
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.